Publication | Closed Access
A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly
41
Citations
11
References
2000
Year
Pharmaceutical ScienceNovel Anthracenedione AnaloguePharmacologyClinical PhasePharmacotherapyMedicineBbr 2778PharmacokineticsDrug DiscoveryDrug Resistance
| Year | Citations | |
|---|---|---|
Page 1
Page 1